Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

MANG - Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn

Company: Hofseth BioCare ASA Date: 2025-09-04 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn

# Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn

HBC is delighted to announce the appointment of Paul Bruhn as Head of New  

Business Development. Mr Bruhn has over 25 years' experience in healthcare and  

the medical nutrition space spanning Novartis Medical Nutrition and Nestle  

Health Science.  

  

He has been leading businesses across multiple geographies including Japan,  

Korea, India, Middle East, Singapore, Canada, Switzerland and Australia and  

hence has an excellent overlap with corporates focused on developing the next  

generation of products targeting clinical nutrition and consumer healthcare.  

  

Mr Bruhn has significant experience working within the medical nutrition, VMS  

and meal replacement categories, across multiple channels.  

  

Mr Bruhn says:  

  

"I am delighted to contribute to the journey of taking HBC to the next level,  

particularly given the acceleration of business in Asia, China and across the  

ANZ region. I believe there is a market need for new clinically backed sources  

of nutrition, and the specialty ingredients from Hofseth BioCare fill that gap.  

  

HBC has developed a unique portfolio of bioactive ingredients called OmeGo®,  

ProGo®, NT-II(TM) and PetGo®, derived from salmon, that are backed by science and  

are fully sustainable, ensuring that the whole salmon is fully utilized. For  

example, OmeGo®, unlike regular highly processed Omega 3 fish oils, is a full  

spectrum salmon oil containing all the Omega fatty acids found in fresh whole  

fish, is 100% natural and proven to be more absorbable with clinical evidence to  

support anti-inflammation, supports heart health & has anti-allergy benefits.  

These ingredients will ensure differentiation in large product categories that  

are craving for innovation. I look forward to help putting them into leading  

brands."  

  

For further information, please contact:  

  

James Berger, CCO at Hofseth BioCare ASA  

Phone: +41 79 950 1034  

E-mail: jb@hofsethbiocare.no  

  

About Hofseth BioCare ASA:  

  

HBC is a Norwegian consumer and pet health company founded on the core values of  

sustainability, optimal utilization of natural resources and full traceability.  

It upcycles the side streams of the salmon industry by taking fresh filleted  

salmon and converting it from a waste product into ingredients to improve human  

and pet health.  

  

These ingredients are ProGo®, a mix of bioactive peptides and collagen, OmeGo®,  

a whole salmon oil, with all the fatty acid fractions contained in fish, and  

CalGo® / NT-II® salmon bone powder containing calcium hydroxyapatite and  

undenatured collagen for bone and joint health.  

  

HBC places scientific evidence at the forefront which has led to important  

academic partnerships and the identification of unique health benefits. This  

includes the demonstration of improved iron metabolism by boosting the body's  

ability to take up and use iron resulting in increased energy and vitality with  

ProGo® as well as the activation of the GLP-1 receptor with fat reduction in  

overweight adults. OmeGo® has shown important immune health benefits including  

recovery from viral infection and improved respiratory health and sleep in  

adults troubled by particulate matter pollution. Finally, CalGo® has shown both  

bone and joint health benefits to support healthy ageing and active lifestyles.  

  

This work has also resulted in the granting of a number of patents protecting  

these discoveries. It has also led to the discovery of potential therapeutics  

and HBC has spun out a biotech-focused company, HBC Immunology (HBCI) has raised  

external finance, and the lead program is in prostate cancer followed by ovarian  

cancer. A separate molecule is targeted as an oral, steroid-sparing therapy for  

asthma. HBC's headquarters are in Ålesund, Norway with branches in Oslo, London,  

Zürich, Los Angeles and Palo Alto.  

  

HBC is listed on Oslo Stock Exchange with ticker "HBC".

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.